Loading...
This week, NEJM Journal Watch is bringing you coverage of study findings presented virtually at the European Society of Cardiology's annual meeting. Here is a compilation of our coverage to date, listed by title of NEJM Journal Watch summary, with the study article's first author in parentheses. (Your NEJM Journal Watch subscription is required.)
The SGLT-2 inhibitor improved outcomes for patients with heart failure and preserved ejection fraction. Read the summary.
It's unlikely — and empagliflozin's effect on renal outcomes is clearly not a reliable surrogate for its effect on heart failure outcomes. Read the summary.
A large randomized trial suggests that 1 month of dual antiplatelet therapy provides similar clinical outcomes and a lower bleeding risk than 3- to 6-month regimens in this difficult-to-treat patient subset. Read the summary.
Thirty-day survival was not greater with an immediate versus delayed or selective angiographic strategy in this randomized trial. Read the summary.
Early rhythm control worked as well in patients without symptoms as in those with symptoms, according to a prespecified analysis from EAST-AFNET 4. Read the summary.
In a large trial in China, use of a salt substitute with 30% potassium chloride appeared to lower rates of stroke and adverse cardiovascular events. Read the summary.
Outcomes were better with a systolic target of 110 to 130 mm Hg than with a higher target. Read the summary.
Findings of two randomized trials support long-term secondary prevention use but raise questions about short-term use at time of reperfusion. Read the summary.